MA35611B1 - Composé inhibiteur de la signalisation par la voie notch - Google Patents
Composé inhibiteur de la signalisation par la voie notchInfo
- Publication number
- MA35611B1 MA35611B1 MA36712A MA36712A MA35611B1 MA 35611 B1 MA35611 B1 MA 35611B1 MA 36712 A MA36712 A MA 36712A MA 36712 A MA36712 A MA 36712A MA 35611 B1 MA35611 B1 MA 35611B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compound
- signal inhibitor
- notch route
- notch
- route
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne un composé, ou un sel ou hydrate pharmaceutiquement acceptable, et une composition pharmaceutique contenant ledit composé, ou sel ou hydrate pharmaceutiquement acceptable, utile en tant qu'inhibiteur de la signalisation par la voie notch pour le traitement du cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512016P | 2011-07-27 | 2011-07-27 | |
| US201161560486P | 2011-11-16 | 2011-11-16 | |
| PCT/US2012/047100 WO2013016081A1 (fr) | 2011-07-27 | 2012-07-18 | Composé inhibiteur de la signalisation par la voie notch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35611B1 true MA35611B1 (fr) | 2014-11-01 |
Family
ID=46598983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36712A MA35611B1 (fr) | 2011-07-27 | 2014-01-22 | Composé inhibiteur de la signalisation par la voie notch |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8569286B2 (fr) |
| EP (1) | EP2736920B1 (fr) |
| JP (1) | JP6027110B2 (fr) |
| KR (1) | KR101578309B1 (fr) |
| CN (1) | CN103732612B (fr) |
| AP (1) | AP4080A (fr) |
| AR (1) | AR087107A1 (fr) |
| AU (1) | AU2012287251B2 (fr) |
| BR (1) | BR112014001600B1 (fr) |
| CA (1) | CA2841178C (fr) |
| CL (1) | CL2014000175A1 (fr) |
| CO (1) | CO6862159A2 (fr) |
| CR (1) | CR20140036A (fr) |
| CY (1) | CY1116645T1 (fr) |
| DK (1) | DK2736920T3 (fr) |
| DO (1) | DOP2014000011A (fr) |
| EA (1) | EA023044B1 (fr) |
| EC (1) | ECSP14013179A (fr) |
| ES (1) | ES2544937T3 (fr) |
| GT (1) | GT201400012A (fr) |
| HK (1) | HK1194086A1 (fr) |
| HR (1) | HRP20150771T1 (fr) |
| HU (1) | HUE027534T2 (fr) |
| IL (1) | IL229988A (fr) |
| JO (1) | JO3148B1 (fr) |
| MA (1) | MA35611B1 (fr) |
| ME (1) | ME02171B (fr) |
| MX (1) | MX356536B (fr) |
| MY (1) | MY184303A (fr) |
| PE (1) | PE20141061A1 (fr) |
| PL (1) | PL2736920T3 (fr) |
| PT (1) | PT2736920E (fr) |
| RS (1) | RS54135B1 (fr) |
| SI (1) | SI2736920T1 (fr) |
| TW (1) | TWI568730B (fr) |
| WO (1) | WO2013016081A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350216B2 (en) | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| JO3491B1 (ar) * | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20230042756A (ko) | 2016-03-15 | 2023-03-29 | 오리존 지노믹스 에스.에이. | 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물 |
| WO2017180385A1 (fr) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Traitement d'association à base d'inhibiteurs de notch et de pi3k/mtor pour une utilisation dans le traitement du cancer |
| AU2017249078B2 (en) * | 2016-04-12 | 2022-10-20 | Eli Lilly And Company | Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer |
| MA45025A (fr) | 2016-05-20 | 2019-03-27 | Lilly Co Eli | Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1 |
| KR102512899B1 (ko) * | 2016-08-31 | 2023-03-23 | 일라이 릴리 앤드 캄파니 | 고형 종양의 치료를 위한 투약 요법 |
| EP3525796A1 (fr) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Traitement ciblé de lymphome à cellules t matures |
| PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
| ES2949364T3 (es) | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
| CN111902159A (zh) | 2017-11-01 | 2020-11-06 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体 |
| EP3706754A1 (fr) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| JP2021523169A (ja) * | 2018-05-06 | 2021-09-02 | アヤラ ファーマシューティカルズ インコーポレイテッド | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 |
| CA3114113A1 (fr) | 2018-10-02 | 2020-04-09 | Frequency Therapeutics, Inc. | Compositions pharmaceutiques comprenant des agents therapeutiques otiques et procedes associes |
| CN114340611A (zh) | 2019-04-08 | 2022-04-12 | 频率医疗公司 | 用于治疗听力损失的chir99021和丙戊酸的组合 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1171878C (zh) * | 1996-12-23 | 2004-10-20 | 伊兰药品公司 | 化合物、其用途以及含有所述化合物的药物组合物 |
| EP1089977A1 (fr) | 1998-06-22 | 2001-04-11 | Elan Pharmaceuticals, Inc. | Composes destines a inhiber la liberation et/ou la synthese du peptide beta-amyloide |
| JP2002518483A (ja) * | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ，インコーポレイテッド | β−アミロイドペプチド放出を阻害するための化合物および／またはその合成 |
| CN100480248C (zh) | 2003-02-04 | 2009-04-22 | 弗·哈夫曼-拉罗切有限公司 | 用作γ-分泌酶抑制剂的丙二酰胺衍生物 |
| KR20070087233A (ko) | 2003-09-09 | 2007-08-27 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| DK1673347T3 (en) | 2003-10-06 | 2015-10-12 | Hoffmann La Roche | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USED AS GAMMA SECRETASE INHIBITORS |
| CN101410378B (zh) | 2006-03-27 | 2012-12-05 | 霍夫曼-拉罗奇有限公司 | 作为γ分泌酶抑制剂的丙二酰胺衍生物 |
| MX2009007864A (es) * | 2007-02-02 | 2009-07-31 | Hoffmann La Roche | Derivados de 6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-ilo. |
| BRPI0906831A2 (pt) | 2008-01-11 | 2019-09-24 | Hoffmann La Roche | uso de um inibidor de gama-secretase para tratamento de câncer |
| US8637493B2 (en) * | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
-
2012
- 2012-07-10 JO JOP/2012/0190A patent/JO3148B1/ar active
- 2012-07-10 AR ARP120102486A patent/AR087107A1/es not_active Application Discontinuation
- 2012-07-13 TW TW101125459A patent/TWI568730B/zh active
- 2012-07-18 MX MX2014001084A patent/MX356536B/es active IP Right Grant
- 2012-07-18 PL PL12741192T patent/PL2736920T3/pl unknown
- 2012-07-18 BR BR112014001600-3A patent/BR112014001600B1/pt active IP Right Grant
- 2012-07-18 SI SI201230246T patent/SI2736920T1/sl unknown
- 2012-07-18 HU HUE12741192A patent/HUE027534T2/en unknown
- 2012-07-18 AP AP2014007362A patent/AP4080A/en active
- 2012-07-18 PT PT127411924T patent/PT2736920E/pt unknown
- 2012-07-18 CA CA2841178A patent/CA2841178C/fr active Active
- 2012-07-18 AU AU2012287251A patent/AU2012287251B2/en active Active
- 2012-07-18 CN CN201280037471.9A patent/CN103732612B/zh active Active
- 2012-07-18 ME MEP-2015-105A patent/ME02171B/me unknown
- 2012-07-18 DK DK12741192.4T patent/DK2736920T3/en active
- 2012-07-18 EP EP12741192.4A patent/EP2736920B1/fr active Active
- 2012-07-18 KR KR1020147001731A patent/KR101578309B1/ko active IP Right Grant
- 2012-07-18 RS RS20150496A patent/RS54135B1/en unknown
- 2012-07-18 JP JP2014522877A patent/JP6027110B2/ja active Active
- 2012-07-18 MY MYPI2014700183A patent/MY184303A/en unknown
- 2012-07-18 ES ES12741192.4T patent/ES2544937T3/es active Active
- 2012-07-18 EA EA201490161A patent/EA023044B1/ru not_active IP Right Cessation
- 2012-07-18 PE PE2014000129A patent/PE20141061A1/es active IP Right Grant
- 2012-07-18 WO PCT/US2012/047100 patent/WO2013016081A1/fr active Application Filing
- 2012-07-18 US US13/551,681 patent/US8569286B2/en active Active
-
2013
- 2013-12-17 IL IL229988A patent/IL229988A/en active IP Right Grant
-
2014
- 2014-01-22 MA MA36712A patent/MA35611B1/fr unknown
- 2014-01-22 DO DO2014000011A patent/DOP2014000011A/es unknown
- 2014-01-23 CL CL2014000175A patent/CL2014000175A1/es unknown
- 2014-01-24 CR CR20140036A patent/CR20140036A/es unknown
- 2014-01-24 CO CO14014585A patent/CO6862159A2/es active IP Right Grant
- 2014-01-24 GT GT201400012A patent/GT201400012A/es unknown
- 2014-01-27 EC ECSP14013179 patent/ECSP14013179A/es unknown
- 2014-07-22 HK HK14107480.6A patent/HK1194086A1/xx unknown
-
2015
- 2015-07-14 HR HRP20150771TT patent/HRP20150771T1/hr unknown
- 2015-08-25 CY CY20151100742T patent/CY1116645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35611B1 (fr) | Composé inhibiteur de la signalisation par la voie notch | |
| PH12020551062A1 (en) | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA38227A1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase | |
| MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
| MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
| MA37888B1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
| MA38472A1 (fr) | Composé peptidique | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA35275B1 (fr) | Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a | |
| MA34713B1 (fr) | Compose bicyclique | |
| EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
| MA35351B1 (fr) | Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. | |
| EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| MA35107B1 (fr) | Composition pharmaceutique antihypertensive | |
| MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
| MA42776B1 (fr) | Composés utiles pour l'inhibition du ror-gamma-t | |
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| MA37501B1 (fr) | Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines |